Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 24.85% | 16.29% | 8.63% | 4.54% | 5.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.85% | 16.29% | 8.63% | 4.54% | 5.55% |
| Cost of Revenue | 23.02% | 24.06% | 33.34% | 83.84% | 149.13% |
| Gross Profit | 25.55% | 13.81% | 2.27% | -9.91% | -13.40% |
| SG&A Expenses | 41.61% | 33.09% | 26.55% | 13.89% | 4.56% |
| Depreciation & Amortization | 27.43% | 22.79% | 14.72% | 2.94% | -5.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.25% | 23.65% | 15.77% | 9.93% | 4.00% |
| Operating Income | -85.85% | -59.48% | -60.56% | -47.49% | 28.05% |
| Income Before Tax | -250.27% | -153.54% | -150.10% | -128.61% | 119.55% |
| Income Tax Expenses | -176.87% | -167.38% | -143.66% | -112.67% | -45.11% |
| Earnings from Continuing Operations | -270.37% | -146.87% | -152.19% | -132.02% | 1,131.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -270.37% | -146.87% | -152.19% | -132.02% | 1,131.09% |
| EBIT | -85.85% | -59.48% | -60.56% | -47.49% | 28.05% |
| EBITDA | -17.83% | -12.86% | -18.50% | -18.65% | 5.64% |
| EPS Basic | -264.42% | -145.12% | -150.75% | -130.58% | 1,146.57% |
| Normalized Basic EPS | -79.25% | -54.44% | -52.48% | -36.12% | 34.41% |
| EPS Diluted | -267.30% | -146.19% | -151.70% | -131.88% | 1,219.17% |
| Normalized Diluted EPS | -78.92% | -53.92% | -51.95% | -36.04% | 33.64% |
| Average Basic Shares Outstanding | 3.20% | 2.76% | 2.45% | 1.97% | 1.58% |
| Average Diluted Shares Outstanding | 2.06% | 1.84% | 1.15% | 1.28% | 1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |